Altre lingue Active Biotech AB

Azioni

ACTI

SE0001137985

Biotecnologia

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 18:00:00 10/01/2025			Variaz. 5gg	Var. 1 gen.
0,1130 ^SEK	-3,09%		-7,07%	+3,86%

02/01	Precise e Isofol 2024 vincenti sul Nasdaq di Stoccolma, Xbrane e Fingerprint perdenti	FW
19/11	Redeye abbassa il valore motivato di Active Biotech a 0,40 corone svedesi (0,50)	FW

Altre lingue

Active Biotech's nomination committee appointed	18/12
Active Biotech : Positive preclinical tasquinimod data in myelofibrosis presented at ASH 2024 now available on Active Biotech's website	09/12
Positive preclinical tasquinimod data in myelofibrosis presented at ASH 2024 now available on Active Biotech’s website	09/12
Active Biotech Raises SEK43.4 Million from Oversubscribed Rights Offering	19/11
Active Biotech raises SEK 43.4 million in substantially oversubscribed rights issue including exercise of over-allotment option	18/11
Active Biotech : patent for laquinimod in eye disorders will be granted in the US	13/11
Active Biotech’s patent for laquinimod in eye disorders will be granted in the US	13/11
Preclinical data of tasquinimod in myelofibrosis to be presented at ASH 2024	05/11
Active Biotech Announces an Abstract with Preclinical Data for tasquinimod in myelofibrosis At ASH 2024	05/11
Active Biotech Receives EU Approval for Tasquinimod Study	30/10/24
Active Biotech : clinical trial of tasquinimod in myelofibrosis approved in Europe	30/10/24
Active Biotech’s clinical trial of tasquinimod in myelofibrosis approved in Europe	30/10/24
Active Biotech Announces Approval of Clinical Trial of Tasquinimod in Myelofibrosis in Europe	30/10/24
Active Biotech publishes prospectus	28/10/24
Extraordinary General Meeting of Active Biotech AB	23/10/24
Active Biotech : European Patent Office has granted Active Biotech's patent application for eye drop formulation of laquinimod	23/10/24
European Patent Office has granted Active Biotech’s patent application for eye drop formulation of laquinimod	23/10/24
Active Biotech Q3 2024 - Rights Issue Funds Laquinimod	23/10/24
Active Biotech : Interim Report Q3 2024	21/10/24
Active Biotech Interim Report Q3 2024	21/10/24
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	21/10/24
Active Biotech adjusts the terms in the announced rights issue	02/10/24
NOTICE OF EXTRAORDINARY GENERAL MEETING	24/09/24
Active Biotech announces a rights issue of SEK 35 million	23/09/24
Active Biotech reports intriguing intraocular concentrations achieved in a clinical biodistribution study of laquinimod eye drops	10/09/24

Iscriviti per accedere a più notizie

Registrazione 100% gratuita

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Active Biotech AB

Azioni

ACTI

SE0001137985

Biotecnologia

Altre lingue

Filtri